What happens if I overdose Lo / Ovral-28?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include nausea; vaginal bleeding; vomiting.
Proper storage of Lo / Ovral-28:
Store Lo / Ovral-28 at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Lo / Ovral-28 out of the reach of children and away from pets.
Overdose of Lo / Ovral-28 in details
Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.
NON-CONTRACEPTIVE HEALTH BENEFITS
The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of Ethinyl estradiol (Lo / Ovral-28) or 0.05 mg of mestranol.6–11
Effects on menses:
-
Increased menstrual cycle regularity
-
Decreased blood loss and decreased incidence of iron deficiency anemia
-
Decreased incidence of dysmenorrhea
Effects related to inhibition of ovulation:
-
Decreased incidence of functional ovarian cysts
-
Decreased incidence of ectopic pregnancies
Effects from long-term use:
-
Decreased incidence of fibroadenomas and fibrocystic disease of the breast
-
Decreased incidence of acute pelvic inflammatory disease
-
Decreased incidence of endometrial cancer
-
Decreased incidence of ovarian cancer
What should I avoid while taking Lo / Ovral-28?
Smoking can increase your risk of blood clots, stroke, or heart attack caused by Lo / Ovral-28, especially if you are older than 35.
Lo / Ovral-28 will not protect you from sexually transmitted diseases--including HIV and AIDS. Using a condom is the only way to protect yourself from these diseases.
Lo / Ovral-28 warnings
Before the treatment with Lo / Ovral-28 Scoshia Remedy it is necessary to exclude the possibility of a malignant process (especially gastric ulcer) because omeprazole treatment can mask symptoms and delay the correct diagnosis.
Therapy with omeprazole may affects results of laboratory studies of liver and gastrin concentrations in blood plasma.
Due to lack of experience in clinical application of omeprazole this medicine is not recommended for children.
What should I discuss with my healthcare provider before taking Lo / Ovral-28?
Lo / Ovral-28 can cause birth defects. Do not use if you are pregnant. Tell your doctor right away if you become pregnant, or if you miss two menstrual periods in a row. If you have recently had a baby, wait at least 4 weeks before taking Lo / Ovral-28. You should not take Lo / Ovral-28 if you have:
-
untreated or uncontrolled high blood pressure;
-
heart disease (coronary artery disease, uncontrolled heart valve disorder, history of heart attack, stroke, or blood clot);
-
a blood-clotting disorder or circulation problems;
-
problems with your eyes, kidneys or circulation caused by diabetes;
-
a history of hormone-related cancer such as breast or uterine cancer;
-
unusual vaginal bleeding that has not been checked by a doctor;
-
liver disease or liver cancer;
-
severe migraine headaches (with aura, numbness, weakness, or vision changes), especially if you are older than 35;
-
a history of jaundice caused by pregnancy or birth control pills; or
-
if you smoke and are over 35 years old.
To make sure you can safely take Lo / Ovral-28, tell your doctor if you have any of these other conditions:
-
high blood pressure, varicose veins;
-
high cholesterol or triglycerides, or if you are overweight;
-
a history of depression;
-
underactive thyroid;
-
gallbladder disease;
-
diabetes;
-
seizures or epilepsy;
-
a history of irregular menstrual cycles;
-
tuberculosis; or
-
a history of fibrocystic breast disease, lumps, nodules, or an abnormal mammogram.
The hormones in Lo / Ovral-28 can pass into breast milk and may harm a nursing baby. Lo / Ovral-28 may also slow breast milk production. Do not use if you are breast feeding a baby.
Lo / Ovral-28 precautions
GENERAL
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
1. PHYSICAL EXAMINATION AND FOLLOW-UP
It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care.
2. LIPID DISORDERS
Women who are being treated for hyperlipidemias should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult.
3. LIVER FUNCTION
If jaundice develops in any woman receiving oral contraceptives the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function.
4. FLUID RETENTION
Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention.
5. EMOTIONAL DISORDERS
Women with a history of depression should be carefully observed and the drug discontinued if depression recurs to a serious degree.
6. CONTACT LENSES
Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.
7. DRUG INTERACTIONS
Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. A similar association though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, and possibly with griseofulvin, ampicillin, and tetracyclines.76
8. INTERACTIONS WITH LABORATORY TESTS
Certain endocrine and liver function tests and blood components may be affected by oral contraceptives:
-
Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability.
-
Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 concentration is unaltered.
-
Other binding proteins may be elevated in serum.
-
Sex steroid binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged.
-
Triglycerides may be increased.
-
Glucose tolerance may be decreased.
-
Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives.
9. CARCINOGENESIS
10. PREGNANCY
Pregnancy Category X. See CONTRAINDICATIONS and WARNINGS sections.
11. NURSING MOTHERS
Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child.
12. PEDIATRIC USE
Safety and efficacy of Low-Lo / Ovral-28 have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated.
INFORMATION FOR THE PATIENT
What happens if I miss a dose of Lo / Ovral-28?
Follow the patient instructions provided with Lo / Ovral-28. Ask your doctor or pharmacist if you do not understand these instructions. Missing a pill increases your risk of becoming pregnant.
If you miss one active pill, take two pills on the day that you remember. Then take one pill per day for the rest of the pack.
If you miss two active pills in a row in Week 1 or 2, take two pills per day for two days in a row. Then take one pill per day for the rest of the pack. Use back-up birth control for at least 7 days following the missed pills.
If you miss two active pills in a row in Week 3,throw out the rest of the pack and start a new pack the same day if you are a Day 1 starter. If you are a Sunday starter, keep taking a pill every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack that day.
If you miss three active pills in a row in Week 1, 2, or 3, throw out the rest of the pack and start a new pack on the same day if you are a Day 1 starter. If you are a Sunday starter, keep taking a pill every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack that day.
If you miss two or more pills, you may not have a period during the month. If you miss a period for two months in a row, call your doctor because you might be pregnant.
If you miss a reminder pill, throw it away and keep taking one reminder pill per day until the pack is empty. You do not need back-up birth control if you miss a reminder pill.
References
- DailyMed. "ETHINYL ESTRADIOL; NORETHINDRONE ACETATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "ETHINYL ESTRADIOL; NORGESTREL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DrugBank. "norgestrel". http://www.drugbank.ca/drugs/DB09389 (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
